利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.037 秒)

    Compositions for inducing an immune response
    1.
    发明授权
    Compositions for inducing an immune response 有权
    用于诱导免疫反应的组合物

    公开(公告)号：US07361329B2

    公开(公告)日：2008-04-22

    申请号：US10001221

    申请日：2001-10-30

    申请人： Thomas J. Schall ,  Maureen Howard ,  Robert Berkovitz ,  Brett Premack ,  Dale Talbot

    发明人： Thomas J. Schall ,  Maureen Howard ,  Robert Berkovitz ,  Brett Premack ,  Dale Talbot

    IPC分类号： A61K45/00 ,  C07K14/005

    CPC分类号： A61K39/39 ,  A61K2039/55522

    摘要： This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for, among other things, vaccine formulation for therapeutic and prophylactic vaccination (immunization) and for production of useful antibodies (e.g., monoclonal antibodies for therapeutic or diagnostic use).

    摘要翻译： 本申请一般涉及增强免疫应答。 这种免疫应答可以通过疫苗施用引起。 提供了诱导或增强对抗原的免疫应答的组合物和方法。 组合物和方法尤其可用于治疗和预防性接种疫苗（免疫）和生产有用抗体（例如用于治疗或诊断用途的单克隆抗体）的疫苗制剂。

    Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
    2.
    发明授权
    Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof 有权
    可用作甲酰肽受体如1受体的配体的组合物及其使用方法

    公开(公告)号：US08637043B2

    公开(公告)日：2014-01-28

    申请号：US11175003

    申请日：2005-07-05

    申请人： Thomas J. Schall ,  Zhenhua Miao ,  Robert Berahovich ,  Zheng Wei ,  Maureen Howard ,  Brett Premack

    发明人： Thomas J. Schall ,  Zhenhua Miao ,  Robert Berahovich ,  Zheng Wei ,  Maureen Howard ,  Brett Premack

    IPC分类号： A61K39/02

    CPC分类号： C07K14/523 ,  A61K38/00 ,  A61K39/39 ,  A61K2039/55522 ,  Y02A50/39 ,  Y02A50/401 ,  Y02A50/466 ,  Y02A50/484

    摘要： The inventors have discovered that a CKβ8-1 truncation variant, CKβ8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CKβ8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CKβ8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CKβ8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1.This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.

    摘要翻译： 本发明人已经发现CKbeta8-1截短变体CKbeta8-1（25-116）是两种不同GPCR，趋化因子受体CCR1和甲酰肽受体1（FPRL1）的双功能配体。 因此，本发明人发现除了CCR1的功能活性外，CKbeta8-1（25-116）也是通过募集单核细胞和嗜中性粒细胞参与炎症反应和先天免疫的GPCR受体FPRL1的功能性配体。 此外，本发明人已经发现了称为SHAAGTIDE的CKbeta8-1的可变剪接外显子。 SHAAGTIDE与其母体趋化因子CKbeta8-1（25-116）一起在已知表达FPRL1的单核细胞和嗜中性粒细胞上完全起作用。 本申请一般涉及增强免疫应答。 这种免疫应答可以通过疫苗施用引起。 提供了诱导或增强对抗原的免疫应答的组合物和方法。 组合物和方法可用于治疗和预防用途（免疫）和产生抗体的疫苗制剂。

    Enzymatic activities in chemokine-mediated inflammation
    4.
    发明授权
    Enzymatic activities in chemokine-mediated inflammation 有权
    趋化因子介导的炎症中的酶活性

    公开(公告)号：US07572600B2

    公开(公告)日：2009-08-11

    申请号：US11198935

    申请日：2005-08-04

    申请人： Robert D. Berahovich ,  Zhenhua Miao ,  Brett Premack ,  Thomas J. Schall

    发明人： Robert D. Berahovich ,  Zhenhua Miao ,  Brett Premack ,  Thomas J. Schall

    IPC分类号： C12Q1/00 ,  C12Q1/37

    CPC分类号： G01N33/6863 ,  A61K38/00 ,  C07K14/7158 ,  C12Q1/37 ,  G01N2500/00 ,  G01N2800/52

    摘要： Truncated chemokines lacking an N-terminal region that activate CCR1 and/or FPRL1 and compositions containing the truncated chemokines are provided. Methods of identifying agents that modulate CCR1 and/or FPRL1 activity either by modulating the production of the truncated chemokines or the ability of the truncated chemokines to activate CCR1 and/or FPRL1 are also disclosed. Methods using the truncated chemokines to inhibit or activate CCR1 and/or FPRL1 mediated biological activities are also disclosed.

    摘要翻译： 提供缺乏活化CCR1和/或FPRL1的N末端区域的截短趋化因子和含有截短趋化因子的组合物。 还公开了通过调节截短的趋化因子的产生或截短的趋化因子活化CCR1和/或FPRL1的能力来鉴定调节CCR1和/或FPRL1活性的药剂的方法。 还公开了使用截短的趋化因子抑制或激活CCR1和/或FPRL1介导的生物活性的方法。